. Author manuscript; available in PMC: 2020 Aug 1.

Published in final edited form as: J Allergy Clin Immunol. 2019 Aug;144(2):353–360. doi: 10.1016/j.jaci.2019.06.016

Table 1. Emerging therapeutics for chronic pruritus in allergic skin disorders.

MC, mast cell; KC, keratinocyte; AD, atopic dermatitis; PN, prurigo nodularis; CSU, chronic spontaneous urticaria; CPUO, chronic pruritus of unknown origin; ACD, allergic contact dermatitis. Disorders are in bold when therapeutic is FDA-approved.

Target	Source	Therapeutics (target)	Disorder
IL4	Th2, basophil, MC, ILC2	Dupilumab (IL-4RA)	AD
IL-13	Th2, ILC2	Dupilumab (IL-4RA) Tralokinumab (IL-13) Lebrikizumab (IL-13)	AD
IL-33	KC	Etokimab (IL-33)	AD ACD
TSLP	KC	Tezepelumab (TSLP)	AD
IL-31	Th2	Nemolizumab (IL-31RA)	AD PN
IgE	Plasma cells	Omalizumab (IgE)	CSU
JAK	Lymphocytes	Tofacitinib (JAK1/3) Ruxolitinib (JAK1/2) Baricitinib (JAK1/2) Upadacitinib (JAK1) PF-04965842 (JAK1) JTE-052 (pan-JAK)	AD
N1K-R	Neurons	Serlopitant (NK1R)	PN CPUO
Histamine	Basophil, MC, KC	JNJ 39758979 (H4R) ZPL-389 (H4R)	AD CSU
MrgprX2	MC	N/A	CSU